Pharming Group reports first quarter 2024 financial results and provides business update
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST® RUCONEST® revenues increased by 8% to US$46.0 million, compared to the …